US Medical Marijuana Market, Forecast to 2022

US Medical Marijuana Market, Forecast to 2022

Medical Cannabis Revenue will Overtake Recreational in the Next 4 Years

RELEASE DATE
18-Jul-2018
REGION
Global
Research Code: K27E-01-00-00-00
SKU: HC03047-GL-MR_22126

$3,000.00

Special Price $2,250.00 save 25 %

In stock
SKU
HC03047-GL-MR_22126

$3,000.00

$2,250.00 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The medical marijuana market is growing in the United States despite the fact that the Food and Drug Administration (FDA) has not yet approved any medical marijuana products. These marijuana-based products have not yet passed through the rigorous tests and clinical trials required for medical drug approvals in the United States. At the Federal level, marijuana is still considered an illegal Schedule 1 drug. Individual states, however, have laws in place for the legal use of medical marijuana, and in some states, for the use of recreational marijuana. Cannabidiol (CBD) products are also legally available in some US states as well as in many other countries. The market generates a lot of money, though much of that money is still considered a black market.

Many business segments are involved with the development of the medical marijuana market. Some businesses directly touch the plant product, such as growers, packers, transporters, and sellers. Other businesses operate in the medical marijuana industry but do not touch the plant product, including legal services, marketing and brand services, data and analytical services, insurance participants and hardware or software companies. The rules differ depending upon where a company stands related to the marijuana plant. This is a very different model than is in place for traditional pharmaceutical products.

The medical marijuana segment of the marijuana industry includes marijuana plant products, CBD products, and synthetically derived products targeting the cannabidiol receptors CB1 and CB2. There are several synthetic products currently on the markets in many countries other than the US. As a matter of fact, in Canada, not only is medical marijuana approved for use on the national level, its use is covered by Health Canada, the national government insurance plan.

In the US, medical marijuana use is increasing, as many more states have approved it for use in several diseases. In addition, hundreds of clinical trials are underway, testing products under the watchful eye of the FDA. It has been reported in states where medical marijuana is approved for use for the treatment of pain, there have reductions in the use of opioid drugs. This decrease in opioid use may prove to be a valuable mechanism to curb the current opioid epidemic in the US.

Legal uncertainty related to the use of medical marijuana has limited big pharma investments into this space; however in non-US locations, companies are more interested in pursuing this area of research and development. Billions of dollars are being generated through this market. It is a growing market drawing keen interest from physicians, investors and regulators. Physician education will be crucial, as these products gain approval, as cannabis was not a part of the medical curriculum of many currently practicing physicians.

Table of Contents

Key Findings

Scope and Segmentation

Cannabis Segment Overview

CBD Segment Overview

Marijuana Market—Definitions and Market Segments

Market Engineering Measurements

Companies to Watch

3 Big Predictions

Cannabis Primer

Cannabinoids

Endocannabinoid System

Hemp Derived CBD Market

Federal Laws Regarding Cannabis & CBD Regulation

Federal Laws Regarding Hemp Regulation

Federal Oversight in Medical Cannabis Industry

Medical Cannabis—Federal versus State Regulations

State-Specific Approved Marijuana/CBD Use

Medical Marijuana Business Sector Landscape

Medical Cannabis

Medical Cannabis Impact on Opioid Use

Cannabidiol (CBD)

CBD Impact on Healthcare Treatments

Cannabinoid (CB1 & CB2) Drugs in Development

2018 Marijuana Conferences

FDA-Approved Cannabinoid-Based Synthetic Products

Market Opportunities

Disruptive Market Participants

Funding Assessment

Private Company Equity Deals

Medical Marijuana Market—An Overview

Medical Cannabis Revenue by State

Medical Marijuana Forecast by Segment

Key Findings for Medical Cannabis

Transformation in the Medical Marijuana Industry Ecosystem, 2018

Medical Cannabis—Regional Picture

Medical Cannabis—Patients by State

Market Engineering Metrics

Medical Cannabis Revenue Forecast

Revenue Forecast by Sub-segment

Key Findings for CBD

Market Engineering Metrics

CBD Revenue Forecast to 2022

CBD Sub-segment Revenue Forecast

3 Big Predictions

Legal Disclaimer

Appendix—List of Marijuana Industry Keywords & Acronyms

List of Exhibits

List of Figures
  • 1. Medical Cannabis Market: Regulatory Assessment, US, 2018
  • 2. Total Medical Marijuana Market: Geographic Assessment, US, 2018
  • 3. Medical Cannabis Market: Pipeline Assessment, US, 2018
  • 4. Total Medical Marijuana Market: Approved Cannabis-Based Drugs, US, 2016–2017
  • 5. Total Medical Marijuana Market: Companies Funding, US, 2015–2018
  • 6. Total Medical Marijuana Market: Key Market Drivers, US, 2018–2022
  • 7. Total Medical Marijuana Market: Key Market Restraints, US, 2018–2022
  • 8. Medical Cannabis Segment: CBD-Derived Therapies, US, 2018
  • 9. Medical Cannabis Segment: Market Engineering Measurements, US, 2017
  • 10. CBD Segment: Market Engineering Measurements, US, 2017
List of Charts
  • 1. Medical Cannabis Segment: Market Snapshot, US, 2016–2022
  • 2. CBD Segment: Market Snapshot, US, 2016–2022
  • 3. Total Medical Marijuana Market: Market Snapshot, US, 2016–2022
  • 4. Medical Cannabis Segment: Market Engineering Measurements, US, 2017
  • 5. Medical Cannabis Market: Legal Assessment, US, 2018
  • 6. Total Medical Marijuana Market: Sector Analysis, US, 2018
  • 7. CBD Segment: Treatment Type Assessment, US, 2018
  • 8. Medical Cannabis/CBD Market Participants: Disruptive Market Participants, US, 2018
  • 9. Total Private Equity Deals by Country—Cannabis-Based Companies, US, 2012–2016
  • 10. Total Private Equity Deals by State—Cannabis-Based Companies, US, 2012–2016
  • 11. Medical Cannabis Segment: State-Specific Revenue, US, 2018
  • 12. Total Medical Marijuana Market: Revenue Forecast, US, 2016–2022
  • 13. Medical Cannabis Segment: Patient Share by State, US, 2018
  • 14. Medical Cannabis Segment: Revenue Forecast, US, 2016–2022
  • 15. Medical Cannabis Segment: Revenue Forecast by Sub-segments, US, 2016–2022
  • 16. CBD Segment: Revenue Forecast, US, 2016–2022
  • 17. CBD Segment: Revenue Forecast by Sub-segment, US, 2016–2022
Related Research
The medical marijuana market is growing in the United States despite the fact that the Food and Drug Administration (FDA) has not yet approved any medical marijuana products. These marijuana-based products have not yet passed through the rigorous tests and clinical trials required for medical drug approvals in the United States. At the Federal level, marijuana is still considered an illegal Schedule 1 drug. Individual states, however, have laws in place for the legal use of medical marijuana, and in some states, for the use of recreational marijuana. Cannabidiol (CBD) products are also legally available in some US states as well as in many other countries. The market generates a lot of money, though much of that money is still considered a black market. Many business segments are involved with the development of the medical marijuana market. Some businesses directly touch the plant product, such as growers, packers, transporters, and sellers. Other businesses operate in the medical marijuana industry but do not touch the plant product, including legal services, marketing and brand services, data and analytical services, insurance participants and hardware or software companies. The rules differ depending upon where a company stands related to the marijuana plant. This is a very different model than is in place for traditional pharmaceutical products. The medical marijuana segment of the marijuana industry includes marijuana plant products, CBD products, and synthetically derived products targeting the cannabidiol receptors CB1 and CB2. There are several synthetic products currently on the markets in many countries other than the US. As a matter of fact, in Canada, not only is medical marijuana approved for use on the national level, its use is covered by Health Canada, the national government insurance plan. In the US, medical marijuana use is increasing, as many more states have approved it for use in several diseases. In addition, hundreds of clinica
More Information
No Index No
Podcast No
Table of Contents | Executive Summary~ || Key Findings~ || Scope and Segmentation~ || Cannabis Segment Overview~ || CBD Segment Overview~ || Marijuana Market—Definitions and Market Segments~ || Market Engineering Measurements~ || Companies to Watch~ || 3 Big Predictions~ | Market Overview~ || Cannabis Primer~ || Cannabinoids~ || Endocannabinoid System~ || Hemp Derived CBD Market~ || Federal Laws Regarding Cannabis & CBD Regulation~ || Federal Laws Regarding Hemp Regulation~ || Federal Oversight in Medical Cannabis Industry~ || Medical Cannabis—Federal versus State Regulations~ || State-Specific Approved Marijuana/CBD Use~ || Medical Marijuana Business Sector Landscape~ || Medical Cannabis~ || Medical Cannabis Impact on Opioid Use~ || Cannabidiol (CBD)~ || CBD Impact on Healthcare Treatments~ || Cannabinoid (CB1 & CB2) Drugs in Development~ || 2018 Marijuana Conferences~ | Competitive Playbook~ || FDA-Approved Cannabinoid-Based Synthetic Products~ || Market Opportunities~ || Disruptive Market Participants~ || Funding Assessment~ || Private Company Equity Deals~ | Drivers and Restraints—Total Medical Marijuana Market~ || Market Drivers~ || Market Restraints~ | Forecast and Trends—Total Medical Marijuana Market~ || Medical Marijuana Market—An Overview~ || Medical Cannabis Revenue by State~ || Medical Marijuana Forecast by Segment~ | Medical Cannabis Segment~ || Key Findings for Medical Cannabis~ || Transformation in the Medical Marijuana Industry Ecosystem, 2018~ || Medical Cannabis—Regional Picture~ || Medical Cannabis—Patients by State~ || Market Engineering Metrics~ || Medical Cannabis Revenue Forecast~ || Revenue Forecast by Sub-segment~ | CBD Segment~ || Key Findings for CBD~ || Market Engineering Metrics~ || CBD Revenue Forecast to 2022~ || CBD Sub-segment Revenue Forecast~ | The Last Word~ || 3 Big Predictions~ || Legal Disclaimer~ | Appendix~ || Appendix—List of Marijuana Industry Keywords & Acronyms~ || List of Exhibits~ | The Frost & Sullivan Story~
List of Charts and Figures 1. Medical Cannabis Market: Regulatory Assessment, US, 2018~ 2. Total Medical Marijuana Market: Geographic Assessment, US, 2018~ 3. Medical Cannabis Market: Pipeline Assessment, US, 2018~ 4. Total Medical Marijuana Market: Approved Cannabis-Based Drugs, US, 2016–2017~ 5. Total Medical Marijuana Market: Companies Funding, US, 2015–2018~ 6. Total Medical Marijuana Market: Key Market Drivers, US, 2018–2022~ 7. Total Medical Marijuana Market: Key Market Restraints, US, 2018–2022~ 8. Medical Cannabis Segment: CBD-Derived Therapies, US, 2018~ 9. Medical Cannabis Segment: Market Engineering Measurements, US, 2017~ 10. CBD Segment: Market Engineering Measurements, US, 2017~| 1. Medical Cannabis Segment: Market Snapshot, US, 2016–2022~ 2. CBD Segment: Market Snapshot, US, 2016–2022~ 3. Total Medical Marijuana Market: Market Snapshot, US, 2016–2022~ 4. Medical Cannabis Segment: Market Engineering Measurements, US, 2017~ 5. Medical Cannabis Market: Legal Assessment, US, 2018~ 6. Total Medical Marijuana Market: Sector Analysis, US, 2018~ 7. CBD Segment: Treatment Type Assessment, US, 2018~ 8. Medical Cannabis/CBD Market Participants: Disruptive Market Participants, US, 2018~ 9. Total Private Equity Deals by Country—Cannabis-Based Companies, US, 2012–2016~ 10. Total Private Equity Deals by State—Cannabis-Based Companies, US, 2012–2016~ 11. Medical Cannabis Segment: State-Specific Revenue, US, 2018~ 12. Total Medical Marijuana Market: Revenue Forecast, US, 2016–2022~ 13. Medical Cannabis Segment: Patient Share by State, US, 2018~ 14. Medical Cannabis Segment: Revenue Forecast, US, 2016–2022~ 15. Medical Cannabis Segment: Revenue Forecast by Sub-segments, US, 2016–2022~ 16. CBD Segment: Revenue Forecast, US, 2016–2022~ 17. CBD Segment: Revenue Forecast by Sub-segment, US, 2016–2022~
Author Barbara Gilmore
Industries Healthcare
WIP Number K27E-01-00-00-00
Keyword 1 Marijuana
Is Prebook No
GPS Codes 9600-B1,9611-B1